GlassScriptPhysician profile
George B Saffouri
NPI 1962766907
$12,495.74
in general payments reported to CMS, 2019-2025
21 companies · $4,210 in 2025
The $4,210 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,784 · 2020: $105 · 2021: $142 · 2022: $347 · 2023: $734 · 2024: $1,174 · 2025: $4,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,170 · Consulting Fee: $2,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,170.36 |
| Consulting Fee | $2,947.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring International Pharmascience Center US | $4,950.00 | 2019 | |
| Celltrion USA INC. | $3,111.77 | 2024-2025 | Vegzelma, Zymfentra |
| Abbvie INC. | $1,863.49 | 2020-2025 | Rinvoq, Skyrizi, Mavyret |
| Ferring Pharmaceuticals INC. | $712.65 | 2019 | |
| Pfizer INC. | $388.76 | 2019-2025 | |
| Janssen Biotech, INC. | $258.93 | 2022-2025 | Stelara, Tremfya |
| Boston Scientific Corporation | $221.41 | 2024-2025 | Overstitch Endoscopic Suturing System, General - Hemostasis |
| Merck Sharp & Dohme LLC | $169.12 | 2021-2024 | Dificid |
| Lilly USA, LLC | $140.01 | 2024 | Omvoh |
| Ardelyx, INC. | $123.63 | 2023-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $121.82 | 2023 | Zeposia |
| Celgene Corporation | $105.74 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $72.11 | 2024-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.83 | 2024-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $44.46 | 2025 | Wegovy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $39.78 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $33.62 | 2024 | Resmetirom |
| Braintree Laboratories, INC. | $26.19 | 2024 | Suflave, Sutab |
| Nestle Healthcare Nutrition INC. | $21.47 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $17.66 | 2020 | |
| Redhill Biopharma INC. | $13.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Saffouri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.